← All trials
NCT05163561
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2022
- Primary completion
- Oct 31, 2022
- Completion date
- Mar 31, 2023
- First posted
- Dec 20, 2021
- Last posted
- Dec 20, 2021
- Enrollment
- 1072
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Serum Institute of India Pvt. Ltd.Lead sponsor
- International Center for Diarrheal Disease ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.